Authors: Reviewed by Emily Henderson, B.Sc. Jul 19 2022 Medical Science News
An Osaka Metropolitan University research group led by Associate Professor Misako Matsubara of the Department of Veterinary Science, Graduate School of Veterinary Science, and Specially Appointed Professor Katsutoshi Yoshizato of the Department of Hepatology, Graduate School of Medicine, suspected that the innate immune system may prevent SARS-CoV-2 infection; the onset and severity of novel coronavirus (COVID-19) infection are age-dependent, as are the volume and quality of saliva, which are significantly reduced in the elderly.
SARS-CoV-2 is transmitted when the spike protein S1 on the viral envelope binds to the angiotensin-converting enzyme 2 (ACE2) receptor on the membrane of human cells. Saliva and oral cells are important transmission routes for COVID-19 infection. The research group has shown that saliva from SARS-CoV-2 uninfected (healthy) individuals interferes with S1 and ACE2 binding in a concentration-dependent manner. They identified four proteins in saliva that bind to ACE2 and among these proteins, neutrophil elastase and histone H2A markedly inhibit the binding of S1 and ACE2. Neutrophil elastase and H2A are positively charged proteins, which act as a barrier against SARS-CoV-2 binding by covering the negatively charged S1 binding site of ACE2. The research group also showed that cationic polypeptides such as ε-poly-L-lysine are similarly effective in preventing the binding of S1 to ACE2.
This research is the result of a joint study by the Osaka Metropolitan University Graduate School of Medicine and the Graduate School of Veterinary Science, and Cosmo Bio Co., Ltd., and was published online in The Journal of Biochemistry on July 6, 2022.
This study shows that salivary neutrophils are moderately activated by indigenous microorganisms and continuously release a variety of proteins, among which elastase and histone H2A contribute to self-defense against SARS-CoV-2 infection by masking the ACE2 receptor on host cells. We believe that our findings will contribute to the development of methods to not only prevent or treat COVID-19 infection, but also prevent unknown viruses from infecting humans in the future at the innate immune level.”
Professor Katsutoshi Yoshizato, Department of Hepatology, Graduate School of Medicine